Scholarlink

<p>Ovarian cancer is a deadly gynecological malignancy, often detected late with frequent recurrence and treatment resistance. Non-coding RNAs, particularly long non-coding RNAs (lncRNAs), are now recognized as crucial regulators of cancer pathogenesis. This review synthesizes current literature to elucidate the molecular and functional roles of the lncRNA HAGLROS in ovarian cancer, focusing on its interactions within competing endogenous RNA (ceRNA) networks. HAGLROS, located at 2q31.1, is an oncogenic lncRNA that promotes ovarian cancer progression. It drives enhanced cell proliferation, metastasis, and chemotherapy resistance while inhibiting apoptosis. Its oncogenic activity is primarily mediated through intricate sponging interactions with microRNAs (miRNAs), disrupting post-transcriptional gene regulation and influencing epigenetic and transcriptional processes. The dysregulation of HAGLROS underscores its significant role in ovarian tumorigenesis. Its ability to modulate key cancer hallmarks via miRNA interactions reveals complex regulatory axes central to the disease's pathogenesis. HAGLROS represents a promising candidate for early diagnostic biomarkers and novel therapeutic interventions. Further investigation into the HAGLROS–miRNA–mRNA network is essential for defining its clinical utility and developing targeted treatments for ovarian cancer.</p> Graphical abstract <p>HAGLROS as a central oncogenic lncRNA by sponging tumor-suppressor miRNAs leads to the activation of autophagy, proliferation, and chemoresistance, thereby inducing pathogenesis in ovarian cancer.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanistic insights into HAGLROS-mediated therapy resistance in ovarian cancer

  • 期刊论文

  • 发表日期：

    2026年2月3日

查看全文
  • Mohadeseh Sheykhi-Sabzehpoush,
  • Hamed Abedzeydi,
  • Maryam Khombi Shooshtari,
  • Maryam Cheraghzadeh,
  • Farideh Moramezi,
  • Ali Khavanin,
  • Maryam Farzaneh

摘要

Ovarian cancer is a deadly gynecological malignancy, often detected late with frequent recurrence and treatment resistance. Non-coding RNAs, particularly long non-coding RNAs (lncRNAs), are now recognized as crucial regulators of cancer pathogenesis. This review synthesizes current literature to elucidate the molecular and functional roles of the lncRNA HAGLROS in ovarian cancer, focusing on its interactions within competing endogenous RNA (ceRNA) networks. HAGLROS, located at 2q31.1, is an oncogenic lncRNA that promotes ovarian cancer progression. It drives enhanced cell proliferation, metastasis, and chemotherapy resistance while inhibiting apoptosis. Its oncogenic activity is primarily mediated through intricate sponging interactions with microRNAs (miRNAs), disrupting post-transcriptional gene regulation and influencing epigenetic and transcriptional processes. The dysregulation of HAGLROS underscores its significant role in ovarian tumorigenesis. Its ability to modulate key cancer hallmarks via miRNA interactions reveals complex regulatory axes central to the disease's pathogenesis. HAGLROS represents a promising candidate for early diagnostic biomarkers and novel therapeutic interventions. Further investigation into the HAGLROS–miRNA–mRNA network is essential for defining its clinical utility and developing targeted treatments for ovarian cancer.

Graphical abstract

HAGLROS as a central oncogenic lncRNA by sponging tumor-suppressor miRNAs leads to the activation of autophagy, proliferation, and chemoresistance, thereby inducing pathogenesis in ovarian cancer.